Rapid opioid detoxification using opioid antagonists: History, theory and the state of the art

Journal of Addictive Diseases

Volumn 16, Issue 1, 1997, Pages 103-122

  Simon, David L ^a  

^a Nutmeg Intensive Rehab Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; CHLORDIAZEPOXIDE; CLONIDINE; DIAZEPAM; DICYCLOVERINE; HYDROXYZINE; KAOLIN PECTIN; MIDAZOLAM; NALOXONE; NALTREXONE; ONDANSETRON; OPIATE; OPIATE ANTAGONIST; OPIATE RECEPTOR; PARACETAMOL;

ARTICLE; DETOXIFICATION; DRUG DEPENDENCE; HEROIN DEPENDENCE; HUMAN; TECHNIQUE;

HUMANS; LENGTH OF STAY; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; RECEPTORS, OPIOID; TREATMENT OUTCOME; UP-REGULATION;

EID: 0031058863     PISSN: 10550887     EISSN: None     Source Type: Journal    
DOI: 10.1300/J069v16n01_07     Document Type: Article

References (48)

1. Gerra G, Marcato A, Caccavari R, et al. Clonidine and Opiate Receptor Antagonists in the Treatment of Heroin Addiction. Journal of Substance Abuse Treatment 1995; 12(1):35-41.
2. Resnick R, Kastenbaum R, Washton A, et al. Naloxone precipitated withdrawal: a method for rapid induction onto naltrexone. Clin Pharmacol Ther 1977; 21:409-3.
3. Riordan CE, Kleber HD. Rapid opiate detoxification with clonidine and naltrexone. Lancet 1980; 5:1079-80.
4. Charney DS, Riordan CE, Kieber HD, et al. Clonidine and naltrexone: A safe, effective, and rapid treatment of abrupt withdrawal from methadone therapy. Arch Gen Psychiatry 1982; 39:1327-32.
5. Charney DS, Heninger GR, Kleber HD. The combined use of clonidine and naltrexone as a rapid, safe, and effective treatment of abrupt withdrawal from methadone. Am J Psychiatry 1986; 14(7): 831-836.
6. Kleber HD, Topazian M, Gaspari J, et al. Clonidine and naltrexone in the outpatient treatment of heroin withdrawal. Am J Drug Alcohol Abuse 1987; 13(1&2):1-17.
7. Vining E, Kosten TR, Kleber HD. Clinical utility of rapid clonidmenaltrexone detoxification for opioid abusers. British Journal of Addiction 1988; 83:567-575.
8. Brewer C, Hussein R, Bailey C. Opioid withdrawal and naltrexone induction in 48-72 hours with minimal drop-out, using a modification of the naltrexone-clonidine technique. British Journal of Psychiatry 1988; 153:340-3.
9. Zelcer J, White PF. Monitored anesthesia care. Anesthesia, Third Edition, RD Miller editor 1990; 1321-34.
10. Brewer C. Accelerated opioid withdrawal and naltrexone induction in one day. Proceeding of International Congress on Alcohol, Other Drugs & the Family November, 1988, Sidney, Australia.
11. Presslich O, Loimer N. Opiate detoxification under general anesthesia by large doses of naloxone. Clinical Toxicology 1989; 27(4&5):263-270.
12. Loimer N, Schmid RW, Presslich O, Lenz K. Continuous naloxone administration suppresses opiate withdrawal symptoms in human opiate addicts during detoxification treatment. J Psychiat Res 1989; 23(1):81-6.
13. Loimer N, Schmid R, Lenz K, Grunberger J. Acute blocking of naloxone-precipitated opiate withdrawal symptoms by methohexitone. British Journal of Psychiatry 1990; 157:748-52.
14. Senft RA. Experience with clonidine-naltrexone for rapid opiate detoxification. Journal of Substance Abuse Treatment 1991; 8:257-9.
15. Loimer N, Lenz K, Schmid R, Presslich O. Technique for greatly shortening the transition from methadone to naltrexone maintenance of patients addicted to opiates. Am J Psychiatry 1991; 148(7):933-5.
16. Azatian A, Papiasvilli A, Joseph H. A study of the Use of Clonidine and naltrexone in the treatment of opioid addiction in the former USSR. Journal of Addictive Diseases 1994; 13(1):35-52.
17. Legarda JJ, Gossup M. A 24-h inpatient detoxification treatment for heroin addicts: a preliminary investigation. Drug and Alcohol Dependence 1994; 35:91-3.
18. San L, Pulg M, Bulbena A, Farre, M. High Risk of Ultrashort Noninvasive Opiate Detoxification. Am J Psychiatry 1995; 152(6): 956.
19. Smith-Erichsen N, Bo G: Airway closure and fluid filtration in the lung. Br J Anaesth 1979, 51:475.
20. Oswalt CE, Gates GA, Holmstrom EMG: Pulmonary edema as a complication of acute airway obstruction. Rev Surg 34:364, 1977.
21. Brian Zavell from CITA Institute, Beverly Hills, CA.
22. Brochure information from CITA Institute, Beverly Hills, CA.
23. Gooberman LL. Presentation at the American Society of Addiction Medicine 27th Annual Medical-Scientific Conference, Atlanta, Georgia, 1996.
24. Letter from Ohmeda Pharmaceutical Products Division, dated April 9, 1996.
25. Jaffe JH, Martin WR. Opioid Analgesics and Antagonists. Goodman and Gilman's The Pharmacological Basis of Therapeutics, Sixth Edition. 1980, MacMillan Publishing, pp. 523-4.
26. ReVia Package Insert, Rev. 1/95, DuPont Pharma, Wilmington, Delaware 19880.
27. O'Connor PG, Waugh ME, Carroll KM et al. Primary Care-Based Ambulatory Opioid Detoxification: The Results of a Clinical Trial. J Gen Intern Med 1995; 10:255-260.
28. Gold MS. Opiate Addiction and the Locus Coeruleus: The clinical utility of clonidine, naltrexone, methadone and buprenorphine. Psychiatric Clinics of North America 1993; 16(1):61-73.
29. Weiner N. Chapter 9: Drugs that inhibit adrenergic nerves and block adrenergic receptors. Goodman and Gilman's The Pharmacological Basis of Therapeutics, Sixth Edition. 19809 MacMillan Publishing, pp. 202-4.
30. Lebowitz PW, Ramsey FM. Muscle Relaxants. Clinical Anesthesia, Barash et al editors 1989; pp. 340-43.
31. Simon D, Halevy S. The effect of adding sufentanil to one and one-half percent 2-chloroprocaine for continuous epidural analgesia in labor. (Unpublished study.)
32. Bailey PL, Stanley TH. Narcotic Intravenous Anesthetics. Anesthesia, Third Edition, RD Miller editor 1990; p. 312
33. Foo H, Westbrook RF. Naloxone-induced hypoanalgesia: Effects of noradrenergic antagonists and agonist. Pharmacology, Biochemistry and Behavior 1991; 39:795-797.
34. Loimer N, Schmid R, Presslich O and Lenz K. Naloxone treatment for opiate withdrawal syndrome. Br J Psychiatry 1988; 153:851-52.
35. Stoeltin RK. Opioid Agonists and Antagonists. In Pharamacology and Physiology in Anesthcstic Practice. JB Lippincott Co., Philadelphia, PA. 1987; p. 72.
36. Standards of the American Society of Anesthesiologists.
37. Curram MJA. Epidural Analgesia for Labor and Delivery. Anesthesiology Clinics of North America 1990; 8(1):55-73.
38. Messick JM, MacKenzie RA, Nugent M. Anesthesia at Remote Locations. Anesthesia, Third Edition, RD Miller, editor 1990; pp. 2081-85.
39. Herman BH, Czechowicz D. NIDA Scientific Report of Ultra Rapid Detoxification with Anesthesia (UROD): Opinion of the Consultants and Criteria Relating to Evaluating the Safety and Efficacy of UROD, February 23, 1996.
40. Lewin and Associates. Legislative Report on Mental Health and Addiction Services in Connecticut, 1995.
41. Sawicki T. The Miracle Cure? A revolutionary- and highly controversial-treatment for heroin addiction is achieving astounding success in Israel, and is now set to go overseas. The Jerusalem Report, July 13, 1995, pp. 20-21.
42. J. Thomas Payte, Personal communication.
43. Durrett LR, Lawson NW. Autonomic Nervous System Physiology and Pharmacology. Clinical Anesthesia, Barash, Cullen, Stoelting, editors J.B. Lippincott Company, 1989, p. 181.
44. Cvejic S, Trapaidze N, Cyr C, Devi LA. Thr353, located within the COOH-terminal tail of the delta opiate receptor, is involved in receptor down-regulation. J Biol Chem 1996; 27(8):4073-6.
45. Baumhaker Y, Gafni M, Keren O, Same Y. Selective and interactive down-regulation of mu- and delta-opioid receptors in neuroblastoma SK-NSH cells. Mol Pharmacol 1993; 44(2):461-7.
46. Kim DS, Chin H, Klee WA Agonist regulation of the expression of the delta opioid receptor in NG108-15 cells. FEBS letter 1995; 376(1-2):11-4.
47. Yoburn BC, Shah S, Chan K, Duttaroy A, Davis T. Supersensitivity to opioid analgesics following chronic opioid antagonist treatment: relationship to receptor selectivity. Pharmacol Biochem Behav 1995; 51 (2-3):535-9
48. Marley RJ, Shimosato K, Gewiss M, Thomdike E, Goldberg SR, Schindler CW. Long-term sensitization to the behavioral changes in the number of mu and delta opioid receptors in rat brain. Life Sci 1995; 56(10):767-74.